Chapter Clinical Summary
Academic synthesis, diagnostic methodology, and surgical recommendationsSpinal arthrodesis (fusion) is not merely the mechanical implantation of hardware, but a complex biological cascade in which local mechanical stability, graft biology, host biology, vascular supply, and the host bed environment converge to achieve solid osseous consolidation. The biological cascade follows defined phases: initial inflammation and hematoma formation, osteoprogenitor recruitment, revascularization, cartilaginous/woven bone formation (osteogenesis/osteoconduction), and long-term remodeling according to Wolff's law. Autologous bone graft—specifically autologous iliac crest bone graft (ICBG)—remains the historic gold standard due to its complete combination of osteogenesis, osteoinduction, and osteoconduction. However, donor site morbidity has driven the development and widespread use of bone graft substitutes, including allografts (cortical, cancellous, and demineralized bone matrix [DBM]), ceramics (hydroxyapatite, tricalcium phosphate, bioactive glass), bone marrow aspirate concentrates (BMAC), and recombinant osteoinductive growth factors such as bone morphogenetic proteins (rhBMP-2 and rhBMP-7). Understanding graft biology, carrier mechanics, host risk factors (smoking, malnutrition, diabetes, osteoporosis, NSAIDs), and surgical bed preparation is fundamental for preventing pseudarthrosis and achieving durable clinical success.
To present the cellular and molecular biology of bone healing in spinal fusion and evaluate the properties of bone grafts and bone graft substitutes. The reader should be able to understand the triad of osteogenesis, osteoconduction, and osteoinduction; differentiate the advantages, limitations, and indications of autografts, allografts, synthetic ceramics, DBM, cellular bone matrices, and BMPs; identify local and systemic factors influencing fusion; and apply evidence-based principles to graft selection and surgical bed decortication.
Spinal fusion proceeds through four integrated physiological phases: 1) Inflammatory phase (days 0–7), characterized by hematoma formation, platelet degranulation, and cytokine release (TGF-beta, PDGF, FGF, BMPs); 2) Vascular and osteoprogenitor recruitment phase (weeks 1–4), where neoangiogenesis provides oxygen and mesenchymal stem cells migrate into the graft; 3) Osteogenic and bone formation phase (months 1–6), synthesizing immature woven bone through intramembranous or endochondral ossification; and 4) Remodeling phase (months 6–24+), where osteoclastic resorption and osteoblastic deposition reorganize woven bone into lamellar trabecular bone adapted to axial load vectors (Wolff's law).
A successful graft possesses one or more properties of the biological triad: 1) Osteogenesis: the presence of viable, living osteoblasts and mesenchymal progenitor cells capable of de novo bone formation; 2) Osteoinduction: the recruitment and biochemical stimulation of undifferentiated stem cells into osteoblastic lineages by bioactive growth factors (e.g., BMPs, TGF-beta); 3) Osteoconduction: the provision of a three-dimensional structural scaffolding with appropriate porosity (100–500 micrometers) that permits cellular adhesion, fibrovascular ingrowth, and mineralized matrix deposition.
Autologous bone graft (iliac crest or local bone harvested during laminectomy/facetectomy) provides all three triad elements. Allografts (fresh-frozen or freeze-dried) provide osteoconduction and varying structural load support but lack viable osteogenic cells and carry minor immunogenicity. Demineralized bone matrix (DBM) preserves native collagen scaffolding and residual osteoinductive BMPs. Synthetic ceramics (hydroxyapatite [HA], beta-tricalcium phosphate [beta-TCP], biphasic calcium phosphate, and bioactive glass) are purely osteoconductive matrix extenders. Bone Morphogenetic Protein-2 (rhBMP-2) is a potent osteoinductive cytokine delivered via an absorbable collagen sponge (ACS) that reliably induces robust bone formation, though it requires strict dose control to prevent complications such as seroma formation, osteolysis, and heterotopic ossification.
Systemic host factors substantially impact fusion rates: nicotine use and smoking reduce microvascular perfusion; uncontrolled diabetes mellitus impairs osteoblast function; malnutrition (albumin < 3.5 g/dL) starves bone synthesis; chronic steroid or high-dose NSAID therapy inhibits early inflammatory signaling; and severe osteoporosis decreases anchorage. Locally, meticulous surgical decortication of transverse processes, lamina, or vertebral endplates exposes vascularized cancellous bleeding bone ("the garden bed"). Interbody cages provide immediate mechanical distraction, prevent graft compression beyond physiological tolerance, and shield the fusion mass from destructive shear forces.
Graft selection must be tailored to fusion environment, mechanical load, and patient risk profile. For anterior/interbody fusion (ALIF, LLIF, TLIF), local bone combined with osteoconductive ceramics, DBM, or BMP-2 inside a lordotic cage achieves excellent fusion rates due to high compressive loads and rich endplate vascularity. For posterolateral gutter fusion (PLF), where tensile forces predominate and vascularity is lower, autologous bone, DBM with BMAC, or rhBMP-2 are preferred. Meticulous decortication down to bleeding bone without breaching the structural subchondral plate in interbody spaces prevents cage subsidence while maximizing cellular delivery. In high-risk patients (smokers, revision surgery, multi-level deformity, metabolic bone disease), aggressive optimization (smoking cessation >6 weeks preoperatively, glycemic control HbA1c < 7.5%, teriparatide/anabolic therapy for osteoporosis) and judicious use of osteoinductive enhancers are essential to prevent pseudarthrosis and hardware breakage.